Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

@article{Dalesio2000MaximumAB,
  title={Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials},
  author={Otilia Dalesio and Harm van Tinteren and Mike Clarke and Richard Peto and Fritz H. Schr{\"o}der and I Dechering and Vaughan Evans and Jon Godwin and B A Blumenstein and Crawford and Louis J. Denis and Hall Rr and Catherine Hill and Peter Iversen and William U. Shipley and Mark Soloway and Richard J. Sylvester and Collaborat Pct.},
  journal={The Lancet},
  year={2000},
  volume={355},
  pages={1491-1498}
}
BACKGROUND In advanced prostate cancer, androgen suppression (AS) by surgery or drugs controls testicular hormone secretion, and the further addition of an antiandrogen such as nilutamide, flutamide, or cyproterone acetate is referred to as maximum androgen blockade (MAB). The aim of this overview was to compare the effects on the duration of survival of MAB and of AS alone. METHODS The collaborative meta-analysis of 27 randomised trials involved central reanalysis of the data on each of 8275… 
Experiences in Advanced and Metastatic Prostate Cancer
TLDR
Results of meta-analyses conducted to evaluate whether MAB prolongs overall survival in patients with advanced prostate cancer are discussed and trials and case histories examining the use of MAB using the NSAA bicalutamide are presented.
Monotherapy versus combined androgen blockade in patients with advanced prostate cancer
TLDR
The authors designed their review to assess the overall survival outcome, quality of life, disease specific survival, progression-free survival, time-to-treatment failure, and adverse effects, and performed analysis to compare groups including different clinical disease stages.
Triple-arm androgen blockade for advanced prostate cancer: a review
TLDR
The current knowledge regarding androgen resistance, newer androgen inhibition therapies, and the implications of a triple-arm anti-androgen blockade in advanced prostate cancer are summarized.
Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease
  • F. Labrie
  • Medicine
    Molecular and Cellular Endocrinology
  • 2002
TLDR
In the six studies performed in localized or locally advanced disease, the improved cancer-specific survival ranges between 37 and 81% at 5 years of follow-up for patients who received androgen blockade.
Review: maximum androgen blockade does not confer additional survival benefit to androgen suppression in prostate cancer
TLDR
A survival benefit was shown in studies for which nilutamide or flutamide was used as the antiandrogen, and a decrease in survival occurred in trials that used cyproterone acetate (P = 0.04).
Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials.
  • S. Niraula, L. Le, I. Tannock
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
TLDR
There is fair evidence to recommend use of IAD instead of CAD for the treatment of men with relapsing, locally advanced, or metastatic prostate cancer who achieve a good initial response to androgen deprivation, resulting in less cost, inconvenience, and potential toxicity.
Hormone Therapy For Prostate Cancer
TLDR
There is no convincing evidence that neo-adjuvant hormone therapy combined with radical prostatectomy provides long-term efficacy and data from randomised trials and meta-analyses do not provide strong evidence that immediate hormone therapy clearly improves overall survival, although progression-free survival may be prolonged in patients with lymph node positive disease.
Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?
TLDR
Long-term and continuous CAB offers the possibility of long-term control or possible cure of localized prostate cancer, and the serum PSA level rapidly decreased to undetectable levels when CAB was restarted and remained at such low levels afterward.
Combined androgen blockade for prostate cancer: Review of efficacy, safety and cost‐effectiveness
TLDR
The feasibility of CAB with bicalutamide for the treatment of prostate cancer is discussed by reviewing the theoretical background of Cab and then the results of RCT conducted in the 1990s when the usefulness ofCAB was assessed.
Broadening horizons in medical management of prostate cancer
TLDR
Clinical trials suggest that intermittent androgen deprivation therapy (ADT) provides equal or longer time to castration-independence than continuous ADT, and is preferred, especially since there are subtle long-term toxicities associated with ADT.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 28 REFERENCES
Complete Androgen Blockade versus Chemical Castration in Advanced Prostatic Cancer: Analysis of an Italian Multicentre Study
TLDR
This study appears to confirm that the advantages of first-line CAB in CaP are at best marginal, and the outcome did not show any clear advantage for CAB.
Combination treatment versus LHRH alone in advanced prostatic cancer.
TLDR
There is a positive trend in the combination treatment arm in patients with good prognostic factors, and no significant statistical difference was observed between the two groups in overall survival and in time to progression, but probably too few patients were enrolled in each treatment arm to give a statistical interpretation of results.
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
TLDR
Treatment with le uprolide and flutamide is superior to treatment with leuprolide alone in patients with advanced prostate cancer, and Symptomatic improvement was greatest during the first 12 weeks of the combined androgen blockade.
Maximal Androgen Blockade: Final Analysis of EORTC Phase III Trial 30853
TLDR
Increased time to progression and duration of survival is achieved by the combination of flutamide and goserelin when compared to bilateral orchiectomy, according to a prospective, randomized phase III study in patients with metastatic prostate cancer.
A case for synchronous reduction of testicular androgen, adrenal androgen and prolactin for the treatment of advanced carcinoma of the prostate.
TLDR
It is suggested that a combined maximal suppression of androgens and Prolactin offers a significant improvement in response over conventional treatments without prolactin suppression in the treatment of advanced prostatic cancer.
Total androgen suppression: experience from the Scandinavian Prostatic Cancer Group Study No. 2.
TLDR
The Kaplan-Meier analyses showed that time to progression as well as time to death for patients treated with castration+placebo are identical to that for patientstreated withCastration+PCA.
Evaluation of total versus partial androgen blockade in the treatment of advanced prostatic cancer.
TLDR
The preliminary data fail to demonstrate a superiority of total androgen blockade over partial androgens blockade in the treatment of patients with advanced cancer of the prostate.
Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients).
TLDR
The combination of nilutamide and orchidectomy has a beneficial effect on pain of metastatic origin, levels of tumour markers, the objective response of disease and the time to disease progression, and this treatment combination might also improve survival.
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
TLDR
The addition of flutamide to bilateral orchiectomy does not result in a clinically meaningful improvement in survival among patients with metastatic prostate cancer.
Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate--an Australian multicentre trial.
TLDR
This study was not sufficiently powerful to detect small differences in outcome but nevertheless failed to show any benefit for maximal androgen blockade over orchidectomy in this group of patients.
...
1
2
3
...